Kun Wang1, Xianlin Xu2, Min Fan1. 1. Department of Surgical Urology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China. 2. Department of Surgical Urology, Sir Run Run Hospital, Nan Jing Medical University, Nanjing, 211100, Jiangsu, China. xuxianlin2014@sina.com.
Abstract
OBJECTIVE: The aim of this meta-analysis was to evaluate the efficacy of basiliximab versus antithymocyte globulin for induction therapy in renal allograft. METHODS: Medline (PubMed), Embase, Ovid, Cochrane, and the Chinese Biomedical Literature databases were searched to identify prospective randomized controlled trials that compared basiliximab with antithymocyte globulin (ATG) for induction therapy in renal transplantation. RevMan 5.1 software and Stat Manager V4.1 software were used for the meta-analysis. RESULTS: Eight RCTs were included, including a total of 1153 patients. Of these, 547 (47%) had received basiliximab, and 606 (53%) had received ATG. The pooled results revealed that the basiliximab had a lower rate of neoplasm compared with ATG [odds ratio (OR) 0.26; 95% confidence interval (CI) 0.08-0.78; P = 0.02]. There were no significant differences between the two drugs regarding 1-year acute rejection rate (OR 1.32; 95% CI 0.93-1.87; P = 0.13), 1-year graft survival rate (OR 0.73; 95% CI 0.45-1.18; P = 0.20), 1-year patient survival rate (OR 0.52; 95% CI 0.27-1.02; P = 0.06), 1-year infection rate (OR 0.90; 95% CI 0.48-1.68; P = 0.73). CONCLUSION: Induction therapy of basiliximab has similar short-time effects on the recipients in renal transplantation compared with that of ATG. However, regarding the long-term effect, as represented by the rate of neoplasm, basiliximab has a significant advantage.
OBJECTIVE: The aim of this meta-analysis was to evaluate the efficacy of basiliximab versus antithymocyte globulin for induction therapy in renal allograft. METHODS: Medline (PubMed), Embase, Ovid, Cochrane, and the Chinese Biomedical Literature databases were searched to identify prospective randomized controlled trials that compared basiliximab with antithymocyte globulin (ATG) for induction therapy in renal transplantation. RevMan 5.1 software and Stat Manager V4.1 software were used for the meta-analysis. RESULTS: Eight RCTs were included, including a total of 1153 patients. Of these, 547 (47%) had received basiliximab, and 606 (53%) had received ATG. The pooled results revealed that the basiliximab had a lower rate of neoplasm compared with ATG [odds ratio (OR) 0.26; 95% confidence interval (CI) 0.08-0.78; P = 0.02]. There were no significant differences between the two drugs regarding 1-year acute rejection rate (OR 1.32; 95% CI 0.93-1.87; P = 0.13), 1-year graft survival rate (OR 0.73; 95% CI 0.45-1.18; P = 0.20), 1-year patient survival rate (OR 0.52; 95% CI 0.27-1.02; P = 0.06), 1-year infection rate (OR 0.90; 95% CI 0.48-1.68; P = 0.73). CONCLUSION: Induction therapy of basiliximab has similar short-time effects on the recipients in renal transplantation compared with that of ATG. However, regarding the long-term effect, as represented by the rate of neoplasm, basiliximab has a significant advantage.
Authors: A Al Najjar; I Etienne; P Le Pogamp; F Bridoux; Y Le Meur; O Toupance; C Mousson; S Caillard; B Hurault de Ligny; J F Marlière; Y Lebranchu Journal: Transplant Proc Date: 2006-09 Impact factor: 1.066
Authors: S Martínez-Vaquera; M D Navarro Cabello; M López-Andreu; J M Dueñas Jurado; C Rodelo Haad; R Ortega Salas; A Rodríguez Benot; J P Campos Hernández; J C Robles Arista; P Aljama Journal: Transplant Proc Date: 2013 Impact factor: 1.066
Authors: Daniel C Brennan; John A Daller; Kathleen D Lake; Diane Cibrik; Domingo Del Castillo Journal: N Engl J Med Date: 2006-11-09 Impact factor: 91.245
Authors: Marcelo Cantarovich; Antoine Durrbach; Christian Hiesse; Martin Ladouceur; Gerard Benoit; Bernard Charpentier Journal: Transplantation Date: 2008-12-27 Impact factor: 4.939
Authors: Hatem Ali; Karim M Soliman; Ihab Shaheen; Jon Jin Kim; Mohsen El Kossi; Ajay Sharma; Ravi Pararajasingam; Ahmed Halawa Journal: Int Urol Nephrol Date: 2020-03-13 Impact factor: 2.370
Authors: Tambi Jarmi; Samir Khouzam; Nitika Shekhar; Meray Hosni; Launia White; David O Hodge; Martin L Mai; Hani M Wadei Journal: J Clin Med Res Date: 2020-12-18